Recognition of Lipid A Variants by the TLR4-MD-2 Receptor Complex
Overview
Infectious Diseases
Microbiology
Authors
Affiliations
Lipopolysaccharide (LPS) is a component of the outer membrane of almost all Gram-negative bacteria and consists of lipid A, core sugars, and O-antigen. LPS is recognized by Toll-like receptor 4 (TLR4) and MD-2 on host innate immune cells and can signal to activate the transcription factor NFκB, leading to the production of pro-inflammatory cytokines that initiate and shape the adaptive immune response. Most of what is known about how LPS is recognized by the TLR4-MD-2 receptor complex on animal cells has been studied using Escherichia coli lipid A, which is a strong agonist of TLR4 signaling. Recent work from several groups, including our own, has shown that several important pathogenic bacteria can modify their LPS or lipid A molecules in ways that significantly alter TLR4 signaling to NFκB. Thus, it has been hypothesized that expression of lipid A variants is one mechanism by which pathogens modulate or evade the host immune response. Additionally, several key differences in the amino acid sequences of human and mouse TLR4-MD-2 receptors have been shown to alter the ability to recognize these variations in lipid A, suggesting a host-specific effect on the immune response to these pathogens. In this review, we provide an overview of lipid A variants from several human pathogens, how the basic structure of lipid A is recognized by mouse and human TLR4-MD-2 receptor complexes, as well as how alteration of this pattern affects its recognition by TLR4 and impacts the downstream immune response.
Determining the LPS structural features that influence TLR4 downstream signaling.
Manivannan K, Fathy Mohamed Y, Fernandez R Front Microbiol. 2025; 16:1540534.
PMID: 40071202 PMC: 11895810. DOI: 10.3389/fmicb.2025.1540534.
Microbial Trojan Horses: Virulence Factors as Key Players in Neurodegenerative Diseases.
Grahl M, Hohl K, Smaniotto T, Carlini C Molecules. 2025; 30(3).
PMID: 39942791 PMC: 11820544. DOI: 10.3390/molecules30030687.
Velimirov B, Velimirov B Life (Basel). 2025; 14(12.
PMID: 39768292 PMC: 11678573. DOI: 10.3390/life14121584.
Endotoxin-Free Outer Membrane Vesicles for Safe and Modular Anticancer Immunotherapy.
Chen M, Cheng T, Pan Y, Mou C, Chiang Y, Lin W ACS Synth Biol. 2025; 14(1):148-160.
PMID: 39763210 PMC: 11744915. DOI: 10.1021/acssynbio.4c00483.
Regulation of lipid storage and inflammation in the liver by CEACAM1.
Najjar S, Shively J Eur J Clin Invest. 2024; 54 Suppl 2:e14338.
PMID: 39674882 PMC: 11646288. DOI: 10.1111/eci.14338.